- NCIt
- C8101
Loading cancer entity…
Loading cancer entity…
Clinical trials
1,164 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04353375 | HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 / Phase 3 | 235 | HutchmedINDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06383884 | Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion | recruiting | Phase 2 | 30 | Samsung Medical CenterOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06439888 |
| Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer(LySATRA) |
| recruiting |
| Phase 1 / Phase 2 |
| 58 |
| Gustave Roussy, Cancer Campus, Grand ParisOTHER |
| 1 |
| Dec 1, 2025 |
| clinicaltrials |
| NCT04643418 | Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 81 | MegaPro Biomedical Co. Ltd.INDUSTRY | 1 | Nov 3, 2025 | clinicaltrials |
| NCT04972110 | Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors(ATTACC) | terminated | Phase 1 / Phase 2 | 156 | Repare TherapeuticsINDUSTRY | 1 | Oct 30, 2025 | clinicaltrials |
| NCT05597839 | Study of DF9001 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 24 | Dragonfly TherapeuticsINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT06228326 | A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs(KYANITE-1) | recruiting | Phase 1 / Phase 2 | 250 | Krystal Biotech, Inc.INDUSTRY | 1 | Oct 24, 2025 | clinicaltrials |
| NCT04954599 | Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI | recruiting | Phase 1 / Phase 2 | 126 | Maastricht University Medical CenterOTHER | 3 | Oct 7, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT00712712 | Morphine After Radiofrequency Ablation of Painful Bone Metastases in Patients With Cancer(MEDOR) | completed | Phase 2 | 78 | Institut BergoniéOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 143 | MacroGenicsINDUSTRY | 4 | Jul 31, 2025 | clinicaltrials |
| NCT04729348 | Pembrolizumab And Lenvatinib In Leptomeningeal Metastases | terminated | Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | HutchmedINDUSTRY | 1 | Jul 14, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT03520075 | Study of ASTX029 in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 192 | Taiho Oncology, Inc.INDUSTRY | 4 | Jul 3, 2025 | clinicaltrials |
| NCT00540982 | Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction | completed | Phase 1 / Phase 2 | 47 | City of Hope Medical CenterOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT03094169 | AVID100 in Advanced Epithelial Carcinomas | terminated | Phase 1 / Phase 2 | 49 | Formation BiologicsINDUSTRY | 1 | Jun 11, 2025 | clinicaltrials |
| NCT00238355 | Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems | terminated | Phase 2 | 13 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT05736731 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression(EVEREST-1) | active not recruiting | Phase 1 / Phase 2 | 160 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT05435339 | A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy | terminated | Phase 1 / Phase 2 | 31 | GenmabINDUSTRY | 2 | Apr 22, 2025 | clinicaltrials |
| NCT06911333 | AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors(AD1208) | recruiting | Phase 1 / Phase 2 | 36 | Avelos Therapeutics Inc.INDUSTRY | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06895733 | Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1) | recruiting | Phase 1 / Phase 2 | 65 | Tianjin Medical University Second HospitalOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT04585035 | Study to Evaluate D-1553 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 180 | InventisBio Co., LtdINDUSTRY | 4 | Mar 18, 2025 | clinicaltrials |
| NCT04761198 | A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors | completed | Phase 1 / Phase 2 | 76 | Mereo BioPharmaINDUSTRY | 2 | Mar 17, 2025 | clinicaltrials |
| NCT04597541 | A Study of AK112 for Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 59 | AkesoINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT06032845 | Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)(CASTLE-11) | recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04165330 | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 56 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT05559541 | Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | AkesoINDUSTRY | 1 | Feb 19, 2025 | clinicaltrials |
| NCT05669430 | A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 365 | GV20 TherapeuticsINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT05662397 | A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody | active not recruiting | Phase 1 / Phase 2 | 77 | HotSpot Therapeutics, IncINDUSTRY | 3 | Feb 4, 2025 | clinicaltrials |
| NCT06524804 | A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 60 | Chengdu Baiyu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04020185 | Safety and Efficacy Study of IMSA101 in Refractory Malignancies | completed | Phase 1 / Phase 2 | 40 | ImmuneSensor Therapeutics Inc.INDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT01217411 | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06003621 | Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients(MoST-TAP) | recruiting | Phase 2 | 96 | OmicoOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06622486 | First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 50 | Egle TherapeuticsINDUSTRY | 2 | Nov 7, 2024 | clinicaltrials |
| NCT04474470 | A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer | completed | Phase 1 / Phase 2 | 52 | TyrNovo Ltd.INDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT04770207 | Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs | recruiting | Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT04946864 | A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer | suspended | Phase 1 / Phase 2 | 65 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Aug 19, 2024 | clinicaltrials |
| NCT04121442 | Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 15 | Buzzard PharmaceuticalsINDUSTRY | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06478108 | Interventional Software for Multi-immunotherapy of Solid Tumors | recruiting | Phase 2 / Phase 3 | 60 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT04803318 | Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors | recruiting | Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06136065 | 68 Gallium-Fibroblast Activating Protein Inhibitors-46 Positron Emission Tomography - Computerized Tomography for Molecular Assessment of Fibroblast Activation and Risk Assessment in Solid Tumors(FAPI) | unknown | Phase 2 | 100 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT04092673 | Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies(Zotatifin) | unknown | Phase 1 / Phase 2 | 30 | Effector TherapeuticsINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT05357898 | Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 20 | SQZ BiotechnologiesINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05074472 | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors | completed | Phase 1 / Phase 2 | 35 | ZielBio, Inc.INDUSTRY | 1 | Jan 29, 2024 | clinicaltrials |
| NCT04983810 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma | unknown | Phase 1 / Phase 2 | 330 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 3 | Jan 25, 2024 | clinicaltrials |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | completed | Phase 1 / Phase 2 | 133 | CytomX TherapeuticsINDUSTRY | 4 | Jan 23, 2024 | clinicaltrials |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 99 | CytomX TherapeuticsINDUSTRY | 4 | Jan 5, 2024 | clinicaltrials |
| NCT06056323 | A Study of HB0045 Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 71 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT03274661 | Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors | completed | Phase 2 | 52 | Baptist Health South FloridaOTHER | 1 | Oct 19, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Dec 31, 2025source: clinicaltrials